Compare FLGT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | IVVD |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 437.1M |
| IPO Year | 2016 | 2021 |
| Metric | FLGT | IVVD |
|---|---|---|
| Price | $20.82 | $0.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $28.33 | $8.75 |
| AVG Volume (30 Days) | 301.5K | ★ 6.3M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | $18,730,000.00 | ★ $53,426,000.00 |
| Revenue This Year | $10.09 | $61.57 |
| Revenue Next Year | $12.18 | $41.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $13.46 | $0.49 |
| 52 Week High | $31.04 | $3.07 |
| Indicator | FLGT | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 72.34 | 41.63 |
| Support Level | $13.91 | $0.73 |
| Resistance Level | $23.70 | $1.01 |
| Average True Range (ATR) | 0.63 | 0.09 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 90.42 | 58.77 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.